title: Full-face injections of variable total doses of abobotulinum toxin type A: A randomized, phase IV clinical trial of safety and efficacy.
abstract: BACKGROUND
  Botulinum toxin type A (BoNT-A) has been used for almost 20 years in cosmetic dermatology to reduce dynamic wrinkles on single or multiple facial areas.
  
  
  OBJECTIVE
  To evaluate the safety and efficacy of full-face treatments with various total doses of abobotulinum toxin A (ABO).
  
  
  METHODS
  A total of 90 participants were enrolled. Subjects had at least two indications for BoNT-A treatments on each third of the face (upper, middle and lower). They were randomized into 3 groups, with pre-defined total dose range of ABO, varying from 120 to 250 U.
  
  
  RESULTS
  Most of the subjects were women (96.5%). The statistically significant improvement from baseline lasted for more than 24 weeks for glabellar lines, and more than 16 weeks for forehead wrinkles and crow's feet, all P<0.001, with no differences between groups. The most frequent adverse event (excessive perioral weakness) was related to high dose in the perioral area.
  
  
  CONCLUSIONS
  This is the first study to compare safety and efficacy of different doses of ABO administered to the entire face simultaneously. As long as the recommended doses are used, concomitant injections of ABO are safe and efficient, with no increase in adverse events.
authors.forename: Doris
authors.initials: D
authors.lastname: Hexsel
authors.forename: Cristiano
authors.initials: C
authors.lastname: Brum
authors.forename: Manoela D
authors.initials: MD
authors.lastname: Porto
authors.forename: Mariana
authors.initials: M
authors.lastname: Soirefmann
authors.forename: Carolina
authors.initials: C
authors.lastname: Siega
authors.forename: Juliana
authors.initials: J
authors.lastname: Schilling-Souza
authors.forename: Ticiana C
authors.initials: TC
authors.lastname: Rodrigues
mesh_terms: D000328:Adult; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D005145:Face; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000008:administration & dosage* / Q000009:adverse effects; D017060:Patient Satisfaction; D011446:Prospective Studies; D011788:Quality of Life; D015595:Skin Aging / Q000187:drug effects*; D011795:Surveys and Questionnaires
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A; C542869:abobotulinumtoxinA